Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.
Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.
As PierianDx grows, two customers weighed in on their experiences with the core product, the Clinical Genomicist Workspace, and its NGS-related services.
The research team established that its model can be used to determine the optimal dose of radiation therapy for individual patients.
A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.
HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.
Based on targeted sequencing data for almost 500 colorectal cancer samples, researchers proposed five prognostically informative mutational groups centered on APC.
Tumor infiltrating cell adoptive cell therapy success in metastatic melanoma patients was associated with DNA methylation and histone acetylation changes.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.